
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9261431/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation. Gut, 2023, 72, 275-294.	12.1	18
2	Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflammatory Bowel Diseases, 2023, 29, 51-61.	1.9	5
3	Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. Gut, 2023, 72, 49-53.	12.1	18
4	Non-invasive metabolic profiling of inflammation in joints and entheses by multispectral optoacoustic tomography. Rheumatology, 2023, 62, 841-849.	1.9	6
5	Residual homing of α4β7-expressing β1 <sup>+</sup> PI16 <sup>+</sup> regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut, 2022, 71, 1551-1566.	12.1	24
6	Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients—a preliminary study. Clinical Oral Investigations, 2022, 26, 1217-1228.	3.0	8
7	Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 672-673.	4.5	0
8	Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients. Photoacoustics, 2022, 25, 100315.	7.8	16
9	Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis. Gut, 2022, 71, 2414-2429.	12.1	26
10	SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth. Cell Death and Disease, 2022, 13, 52.	6.3	11
11	IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. Journal of Crohn's and Colitis, 2022, 16, ii54-ii63.	1.3	21
12	Review and Analysis of German Mobile Apps for Inflammatory Bowel Disease Management Using the Mobile Application Rating Scale: Systematic Search in App Stores and Content Analysis. JMIR MHealth and UHealth, 2022, 10, e31102.	3.7	10
13	lleal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100097.	3.6	9
14	Natural NADH and FAD Autofluorescence as Label-Free Biomarkers for Discriminating Subtypes and Functional States of Immune Cells. International Journal of Molecular Sciences, 2022, 23, 2338.	4.1	13
15	Molecular Endoscopy for the Diagnosis and Therapeutic Monitoring of Colorectal Cancer. Frontiers in Oncology, 2022, 12, 835256.	2.8	1
16	Small but powerful: will nanoparticles be the future stateâ€ofâ€ŧheâ€art therapy for IBD?. Expert Opinion on Drug Delivery, 2022, 19, 235-245.	5.0	2
17	Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against <scp>SARS</scp> – <scp>CoV</scp> â€2 in an Unvaccinated Cohort. Arthritis and Rheumatology, 2022, 74, 783-790.	5.6	9
18	Targeting STAT3 Signaling in COL1+ Fibroblasts Controls Colitis-Associated Cancer in Mice. Cancers, 2022, 14, 1472.	3.7	6

#	Article	IF	CITATIONS
19	SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells. Cells, 2022, 11, 1262.	4.1	5
20	Impact of Epithelial Cell Shedding on Intestinal Homeostasis. International Journal of Molecular Sciences, 2022, 23, 4160.	4.1	20
21	The outcome of patients with inflammatory bowel disease–associated colorectal cancer is not worse than that of patients with sporadic colorectal cancer–a matched-pair analysis of survival. International Journal of Colorectal Disease, 2022, 37, 381-391.	2.2	7
22	Telomerase deficiency reflects age-associated changes in CD4+ T cells. Immunity and Ageing, 2022, 19, 16.	4.2	11
23	IL-9 Producing Tumor-Infiltrating Lymphocytes and Treg Subsets Drive Immune Escape of Tumor Cells in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2022, 13, 859738.	4.8	11
24	Efficient and Easy Conversion of Human iPSCs into Functional Induced Microglia-like Cells. International Journal of Molecular Sciences, 2022, 23, 4526.	4.1	4
25	"HIIT the Inflammationâ€: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction. Nutrients, 2022, 14, 1996.	4.1	13
26	Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets. Clinical and Translational Gastroenterology, 2022, 13, e00494.	2.5	5
27	Labelâ€free analysis of inflammatory tissue remodeling in murine lung tissue based on multiphoton microscopy, Raman spectroscopy and machine learning. Journal of Biophotonics, 2022, 15, .	2.3	2
28	Organoids in gastrointestinal diseases: from experimental models to clinical translation. Gut, 2022, 71, 1892-1908.	12.1	40
29	Rear Window—What Can the Gut Tell Us About Long-COVID?. Gastroenterology, 2022, 163, 376-378.	1.3	6
30	Label-Free Characterization and Quantification of Mucosal Inflammation in Common Murine Colitis Models With Multiphoton Imaging. Inflammatory Bowel Diseases, 2022, 28, 1637-1646.	1.9	2
31	Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210988.	3.2	3
32	Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflammatory Bowel Diseases, 2022, 28, 1746-1755.	1.9	5
33	The Positive Rate of Pulmonary Embolism by CT Pulmonary Angiography Is High in an Emergency Department, Even in Low-Risk or Young Patients. Medical Principles and Practice, 2021, 30, 37-44.	2.4	4
34	How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients with Primary Biliary Cholangitis?. Digestion, 2021, 102, 428-436.	2.3	1
35	Severe Acute Respiratory Syndrome Coronavirus 2 Attachment Receptor Angiotensin-Converting Enzyme 2 Is Decreased in Crohn's Disease and Regulated By Microbial and Inflammatory Signaling. Gastroenterology, 2021, 160, 925-928.e4.	1.3	15
36	Gastric hyperplastic polyps (hyperplasiogenic polyps): a constant debate!. Endoscopy, 2021, 53, 100-100.	1.8	0

#	Article	IF	CITATIONS
37	Inducible mouse models of colon cancer for the analysis of sporadic and inflammation-driven tumor progression and lymph node metastasis. Nature Protocols, 2021, 16, 61-85.	12.0	46
38	Precision of handheld multispectral optoacoustic tomography for muscle imaging. Photoacoustics, 2021, 21, 100220.	7.8	25
39	Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482098280.	3.2	14
40	Rho GTPases as Key Molecular Players within Intestinal Mucosa and GI Diseases. Cells, 2021, 10, 66.	4.1	14
41	IL-36 in chronic inflammation and fibrosis — bridging the gap?. Journal of Clinical Investigation, 2021, 131, .	8.2	57
42	Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterology, 2021, 21, 33.	2.0	10
43	Effects of very low volume high intensity versus moderate intensity interval training in obese metabolic syndrome patients: a randomized controlled study. Scientific Reports, 2021, 11, 2836.	3.3	27
44	Food Intolerance of Unknown Origin: Caused by Mucosal Inflammation? A Pilot Study. Clinical and Translational Gastroenterology, 2021, 12, e00312.	2.5	2
45	Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma. Cancers, 2021, 13, 1183.	3.7	3
46	Intestinal Mucosal Wound Healing and Barrier Integrity in IBD–Crosstalk and Trafficking of Cellular Players. Frontiers in Medicine, 2021, 8, 643973.	2.6	52
47	Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients?. Journal of Crohn's and Colitis, 2021, 15, 697-698.	1.3	2
48	Role of the IL23/IL17 Pathway in Crohn's Disease. Frontiers in Immunology, 2021, 12, 622934.	4.8	84
49	Validation of the â€~Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease. Journal of Crohn's and Colitis, 2021, 15, 1621-1630.	1.3	21
50	Circulating Adaptive Immune Cells Expressing the Gut Homing Marker α4β7 Integrin Are Decreased in COVID-19. Frontiers in Immunology, 2021, 12, 639329.	4.8	8
51	Purple urine in a patient after recovery from a SARS-CoV-2 infection. International Journal of Infectious Diseases, 2021, 105, 472-473.	3.3	2
52	Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus. Frontiers in Medicine, 2021, 8, 641163.	2.6	9
53	Vedolizumab-associated enthesitis: correlation or causality?. Rheumatology, 2021, 60, 5491-5492.	1.9	2
54	Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19. Gut, 2021, 70, 1605-1608.	12.1	34

#	Article	IF	CITATIONS
55	Iron Beats Electricity: Resistance Training but Not Whole-Body Electromyostimulation Improves Cardiometabolic Health in Obese Metabolic Syndrome Patients during Caloric Restriction—A Randomized-Controlled Study. Nutrients, 2021, 13, 1640.	4.1	8
56	Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11. Neoplasia, 2021, 23, 502-514.	5.3	5
57	Comparative Transcriptomics of IBD Patients Indicates Induction of Type 2 Immunity Irrespective of the Disease Ideotype. Frontiers in Medicine, 2021, 8, 664045.	2.6	3
58	Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy. Frontiers in Immunology, 2021, 12, 656452.	4.8	17
59	Dynamic Imaging of IEL-IEC Co-Cultures Allows for Quantification of CD103-Dependent T Cell Migration. International Journal of Molecular Sciences, 2021, 22, 5148.	4.1	5
60	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases, 2021, 80, 1339-1344.	0.9	202
61	SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 2021, 80, 1312-1316.	0.9	154
62	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 705-715.	17.8	26
63	The Ominous Ouzo Party – A Case Series of Four Patients with Accidental Alkali Ingestion. Clinical and Experimental Gastroenterology, 2021, Volume 14, 303-308.	2.3	0
64	Innovative Diagnostic Endoscopy in Inflammatory Bowel Diseases: From High-Definition to Molecular Endoscopy. Frontiers in Medicine, 2021, 8, 655404.	2.6	9
65	E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis. Nature Cell Biology, 2021, 23, 796-807.	10.3	38
66	Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. Cancers, 2021, 13, 3820.	3.7	12
67	The Gut-Brain Axis in Inflammatory Bowel Disease—Current and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 8870.	4.1	36
68	Dynamic, Transient, and Robust Increase in the Innervation of the Inflamed Mucosa in Inflammatory Bowel Diseases. Cells, 2021, 10, 2253.	4.1	4
69	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. New England Journal of Medicine, 2021, 385, 628-639.	27.0	156
70	A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice. Journal of Allergy and Clinical Immunology, 2021, 148, 506-522.e8.	2.9	29
71	Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms. Endocrine-Related Cancer, 2021, 28, 605-620.	3.1	1
72	Mucosal Biofilms Are an Endoscopic Feature of Irritable Bowel Syndrome and Ulcerative Colitis. Gastroenterology, 2021, 161, 1245-1256.e20.	1.3	55

#	Article	IF	CITATIONS
73	COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatology, The, 2021, 3, e724-e736.	3.9	76
74	Targeting of the Tec Kinase ITK Drives Resolution of T Cell–Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis. Gastroenterology, 2021, 161, 1270-1287.e19.	1.3	9
75	Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn's disease patient upon infliximab-induced lupus-like syndrome. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110440.	3.2	3
76	Is histological healing a feasible endpoint in ulcerative colitis?. Expert Review of Gastroenterology and Hepatology, 2021, 15, 665-674.	3.0	12
77	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Archiv Fur Pathologische Anatomie	2.8	26
78	SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications. Visceral Medicine, 2021, 37, 63-69.	1.3	3
79	Visualizing transfer of microbial biomolecules by outer membrane vesicles in microbeâ€hostâ€communication in vivo. Journal of Extracellular Vesicles, 2021, 10, e12159.	12.2	66
80	Bowel wall thickening and hyperemia assessed by high-frequency ultrasound indicate histological inflammation in Crohn's ileitis. Abdominal Radiology, 2021, 46, 1855-1863.	2.1	2
81	Autophagy in Cancer Therapy—Molecular Mechanisms and Current Clinical Advances. Cancers, 2021, 13, 5575.	3.7	12
82	CRISPR/Cas9 in Gastrointestinal Malignancies. Frontiers in Cell and Developmental Biology, 2021, 9, 727217.	3.7	4
83	α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110547.	3.2	1
84	New agents for immunosuppression. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 54-55, 101763.	2.4	2
85	Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. BMJ Open, 2021, 11, e049208.	1.9	9
86	Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment. Frontiers in Pharmacology, 2021, 12, 757120.	3.5	32
87	Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing. Gut, 2020, 69, 252-263.	12.1	80
88	The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 508-524.	1.3	46
89	Environmental Microbial Factors Determine the Pattern of Inflammatory Lesions in a Murine Model of Crohn's Disease–Like Inflammation. Inflammatory Bowel Diseases, 2020, 26, 66-79.	1.9	21
90	Host–microbiota interactions in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 76-77.	17.8	73

#	Article	IF	CITATIONS
91	Assessment of gait parameters and physical function in patients with advanced cancer participating in a 12â€week exercise and nutrition programme: A controlled clinical trial. European Journal of Cancer Care, 2020, 29, e13199.	1.5	16
92	STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut, 2020, 69, 1269-1282.	12.1	181
93	Rationale for IL-36 receptor antibodies in ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 339-342.	3.1	15
94	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 1063-1075.	8.1	35
95	>All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective. ImmunoTargets and Therapy, 2020, Volume 9, 289-297.	5.8	16
96	Low-volume high-intensity interval training improves cardiometabolic health, work ability and well-being in severely obese individuals: a randomized-controlled trial sub-study. Journal of Translational Medicine, 2020, 18, 419.	4.4	21
97	Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine, 2020, 58, 102925.	6.1	369
98	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications, 2020, 11, 3774.	12.8	78
99	Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients. Crohn's & Colitis 360, 2020, 2, otaa037.	1.1	5
100	Topical application of Chlorin e6-PVP (Ce6-PVP) for improved endoscopic detection of neoplastic lesions in a murine colitis-associated cancer model. Scientific Reports, 2020, 10, 13129.	3.3	5
101	Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice. Science Translational Medicine, 2020, 12, .	12.4	9
102	Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. Frontiers in Medicine, 2020, 7, 517.	2.6	70
103	Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. Journal of Molecular Medicine, 2020, 98, 1385-1395.	3.9	34
104	IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients. Cells, 2020, 9, 2676.	4.1	24
105	Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095411.	3.2	13
106	Successful Therapy of Crohn's Disease–Associated Pulmonary Necrobiotic Nodules on Ustekinumab Therapy. American Journal of Gastroenterology, 2020, 115, 632-634.	0.4	1
107	Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?. Visceral Medicine, 2020, 36, 338-342.	1.3	16
108	IL-36 in chronic inflammation and cancer. Cytokine and Growth Factor Reviews, 2020, 55, 70-79.	7.2	33

#	Article	IF	CITATIONS
109	Label-Free InÂVivo Histopathology of Experimental Colitis via 3-Channel Multiphoton Endomicroscopy. Gastroenterology, 2020, 159, 832-834.	1.3	11
110	Immune Cell Circuits in Mucosal Wound Healing: Clinical Implications. Visceral Medicine, 2020, 36, 129-136.	1.3	5
111	Nanoparticles in Gastrooncology. Visceral Medicine, 2020, 36, 88-94.	1.3	7
112	Advanced Endoscopic Imaging in Colonic Neoplasia. Visceral Medicine, 2020, 36, 48-59.	1.3	7
113	Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation. Frontiers in Immunology, 2020, 11, 1062.	4.8	13
114	Physical activity and advanced cancer: evidence of exerciseâ€sensitive genes regulating prostate cancer cell proliferation and apoptosis. Journal of Physiology, 2020, 598, 3871-3889.	2.9	11
115	Intestinal ex vivo organoid culture reveals altered programmed crypt stem cells in patients with celiac disease. Scientific Reports, 2020, 10, 3535.	3.3	25
116	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2526-2534.e9.	4.4	45
117	Viral FLIP blocks Caspase-8 driven apoptosis in the gut in vivo. PLoS ONE, 2020, 15, e0228441.	2.5	5
118	Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. Journal of Clinical Medicine, 2020, 9, 385.	2.4	5
119	COVID-19 and immunomodulation in IBD. Gut, 2020, 69, 1335-1342.	12.1	221
120	Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterology, 2020, 20, 103.	2.0	12
121	Total Recall: Intestinal TRM Cells in Health and Disease. Frontiers in Immunology, 2020, 11, 623072.	4.8	8
122	Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-Extrinsic Manner. Frontiers in Immunology, 2020, 11, 590893.	4.8	5
123	Complementary roles of murine NaV1.7, NaV1.8 and NaV1.9 in acute itch signalling. Scientific Reports, 2020, 10, 2326.	3.3	16
124	PGAM5-MAVS interaction regulates TBK1/ IRF3 dependent antiviral responses. Scientific Reports, 2020, 10, 8323.	3.3	11
125	Double-Balloon Enteroscopy-detected Lipid Islets in the Small Bowel are Strong Predictors of Cardiovascular Disease when associated with Angiectasia and Bleeding. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 33-37.	0.9	1
126	Retrograde inspection <i>vs</i> standard forward view for the detection of colorectal adenomas during colonoscopy: A back-to-back randomized clinical trial. World Journal of Gastroenterology, 2020, 26, 1962-1970.	3.3	5

#	Article	IF	CITATIONS
127	Perforations after routine biopsy in IBD patients, their management and potential risk reductions by microscopic imaging with endocytoscopy. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 465-466.	0.9	0
128	An Intravital Microscopy-Based Approach to Assess Intestinal Permeability and Epithelial Cell Shedding Performance. Journal of Visualized Experiments, 2020, , .	0.3	1
129	Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut, 2019, 68, 814-828.	12.1	146
130	Neutrophil Extracellular Traps Initiate Gallstone Formation. Immunity, 2019, 51, 443-450.e4.	14.3	115
131	Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity, 2019, 51, 367-380.e4.	14.3	76
132	Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985686.	3.2	50
133	Resolution of ulcerative colitis. Seminars in Immunopathology, 2019, 41, 747-756.	6.1	60
134	Citrullination Licenses Calpain to Decondense Nuclei in Neutrophil Extracellular Trap Formation. Frontiers in Immunology, 2019, 10, 2481.	4.8	41
135	Resolution of acute intestinal graft-versus-host disease. Seminars in Immunopathology, 2019, 41, 655-664.	6.1	7
136	Inhibiting PGGT1B Disrupts Function of RHOA, Resulting in T-cell Expression of Integrin α4β7 and Development of Colitis in Mice. Gastroenterology, 2019, 157, 1293-1309.	1.3	21
137	Interferon Lambda Promotes Paneth Cell Death Via STAT1 Signaling in Mice and Is Increased in Inflamed Ileal Tissues of Patients With Crohn's Disease. Gastroenterology, 2019, 157, 1310-1322.e13.	1.3	63
138	Resolution of Crohn's disease. Seminars in Immunopathology, 2019, 41, 737-746.	6.1	16
139	Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nature Immunology, 2019, 20, 288-300.	14.5	152
140	Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Frontiers in Pharmacology, 2019, 10, 39.	3.5	25
141	Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut, 2019, 68, 1688-1700.	12.1	108
142	Acoustic Radiation Force Impulse (ARFI) Elastography in Autoimmune and Cholestatic Liver Diseases. Annals of Hepatology, 2019, 18, 23-29.	1.5	18
143	Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nature Immunology, 2019, 20, 970-979.	14.5	390
144	PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis. Cellular and Molecular Life Sciences, 2019, 76, 4783-4794.	5.4	20

#	Article	IF	CITATIONS
145	Concept to gain trust for a German personal health record system using public cloud and FHIR. Journal of Biomedical Informatics, 2019, 95, 103212.	4.3	10
146	Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis. Zeitschrift Fur Gastroenterologie, 2019, 57, 473-483.	0.5	11
147	Acoustic radiation force impulse (ARFI) shear wave elastography of the bowel wall in healthy volunteers and in ulcerative colitis. Acta Radiologica Open, 2019, 8, 205846011984096.	0.6	8
148	What gastroenterologists and hepatologists should know about organoids in 2019. Digestive and Liver Disease, 2019, 51, 753-760.	0.9	14
149	A Dual Role for TNF-Producing T Cells in the Fetal Intestine. Immunity, 2019, 50, 278-280.	14.3	1
150	Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation. Gastroenterology, 2019, 156, 1082-1097.e11.	1.3	148
151	Targeting Immune Cell Wiring in Ulcerative Colitis. Immunity, 2019, 51, 791-793.	14.3	7
152	Anti-trafficking agents in the treatment of inflammatory bowel disease. Current Opinion in Gastroenterology, 2019, 35, 499-506.	2.3	2
153	Clinical Characteristics of Influenza in Season 2017/2018 in a German Emergency Department: A Retrospective Analysis. Microbiology Insights, 2019, 12, 117863611989030.	2.0	11
154	Resolution of inflammation: from basic concepts to clinical application. Seminars in Immunopathology, 2019, 41, 627-631.	6.1	17
155	Modulation of the extrinsic cell death signaling pathway by viral Flip induces acute-death mediated liver failure. Cell Death and Disease, 2019, 10, 878.	6.3	4
156	Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy. Nature Medicine, 2019, 25, 1905-1915.	30.7	129
157	IL-23 in inflammatory bowel diseases and colon cancer. Cytokine and Growth Factor Reviews, 2019, 45, 1-8.	7.2	142
158	Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. Journal of Crohn's and Colitis, 2019, 13, 267-269.	1.3	43
159	Influence of low FODMAP and gluten-free diets on disease activity and intestinal microbiota in patients with non-celiac gluten sensitivity. Clinical Nutrition, 2019, 38, 697-707.	5.0	89
160	Detection of circulating extracellular mRNAs by modified small-RNA-sequencing analysis. JCI Insight, 2019, 4, .	5.0	29
161	Comparison of Hemospray <sup>®</sup> and Endoclot <sup>â,,¢</sup> for the treatment of gastrointestinal bleeding. World Journal of Gastroenterology, 2019, 25, 1592-1602.	3.3	32
162	Intestinal epithelial Caspase-8 signaling is essential to prevent necroptosis during Salmonella Typhimurium induced enteritis. Mucosal Immunology, 2018, 11, 1191-1202.	6.0	39

#	Article	IF	CITATIONS
163	Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS. European Radiology, 2018, 28, 4254-4264.	4.5	54
164	Endoscopic full-thickness resection with an over-the-scope clip device (FTRD) in the colorectum: results from a university tertiary referral center. Endoscopy International Open, 2018, 06, E98-E103.	1.8	46
165	Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. Gastrointestinal Endoscopy, 2018, 87, 1505-1514.e3.	1.0	25
166	Raster-Scanning Optoacoustic Mesoscopy for Gastrointestinal Imaging at High Resolution. Gastroenterology, 2018, 154, 807-809.e3.	1.3	20
167	Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients. Inflammatory Bowel Diseases, 2018, 24, 35-44.	1.9	25
168	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis, 2018, 12, 610-620.	1.3	67
169	Environmental triggers in IBD: a review of progress and evidence. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 39-49.	17.8	573
170	Whole-Body Electromyostimulation Combined With Individualized Nutritional Support Improves Body Composition in Patients With Hematological Malignancies – A Pilot Study. Frontiers in Physiology, 2018, 9, 1808.	2.8	22
171	Detection by flow cytometry of anti-neutrophil cytoplasmic antibodies in a novel approach based on neutrophil extracellular traps. Autoimmunity, 2018, 51, 288-296.	2.6	7
172	Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease. Journal of Visualized Experiments, 2018, , .	0.3	3
173	Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application. American Journal of Gastroenterology, 2018, 113, 1908-1910.	0.4	9
174	Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2018, 3, 790-802.	8.1	60
175	Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial. BMC Cancer, 2018, 18, 886.	2.6	48
176	Gut–Liver Axis: How Do Gut Bacteria Influence the Liver?. Medical Sciences (Basel, Switzerland), 2018, 6, 79.	2.9	92
177	Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflammatory Bowel Diseases, 2018, 24, 1237-1250.	1.9	33
178	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Digestive and Liver Disease, 2018, 50, 1019-1029.	0.9	20
179	Targeting Inflammatory T Helper Cells via Retinoic Acid-Related Orphan Receptor Gamma t Is Ineffective to Prevent Allo-Response-Driven Colitis. Frontiers in Immunology, 2018, 9, 1138.	4.8	6
180	Chronic intestinal inflammation in mice expressing viral Flip in epithelial cells. Mucosal Immunology, 2018, 11, 1621-1629.	6.0	8

#	Article	IF	CITATIONS
181	Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nature Communications, 2018, 9, 3261.	12.8	272
182	Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. Frontiers in Immunology, 2018, 9, 1700.	4.8	38
183	The importance of pancreatic inflammation in endosonographic diagnostics of solid pancreatic masses. Medical Ultrasonography, 2018, 20, 427.	0.8	8
184	BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. Journal of Clinical Investigation, 2018, 128, 916-930.	8.2	34
185	Confocal Laser Endomicroscopy for Diagnosing Malignant Pleural Effusions. Medical Science Monitor, 2018, 24, 5437-5447.	1.1	9
186	A Novel Mobile Phone App (OncoFood) to Record and Optimize the Dietary Behavior of Oncologic Patients: Pilot Study. JMIR Cancer, 2018, 4, e10703.	2.4	17
187	Identification of Bronchoalveolar Lavage Components Applying Confocal Laser Endomicroscopy. Medical Science Monitor, 2018, 24, 4198-4203.	1.1	2
188	IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo. Gut, 2017, 66, 823-838.	12.1	142
189	Computed Tomography–Guided Percutaneous Gastrostomy/Jejunostomy for Feeding and Decompression. Nutrition in Clinical Practice, 2017, 32, 212-218.	2.4	10
190	PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury. Gut, 2017, 66, 716-723.	12.1	77
191	Top-down approach to biological therapy of Crohn's disease. Expert Opinion on Biological Therapy, 2017, 17, 285-293.	3.1	11
192	Molecular imaging of mucosal α4β7 integrin expression withÂthe fluorescent anti-adhesion antibody vedolizumab inÂCrohn's disease. Gastrointestinal Endoscopy, 2017, 86, 406-408.	1.0	65
193	Current and emerging therapeutic targets for IBD. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 269-278.	17.8	478
194	Blockade of αEβ7 integrin suppresses accumulation of CD8 <sup>+</sup> and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut, 2017, 66, 1936-1948.	12.1	99
195	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet, The, 2017, 389, 1699-1709.	13.7	364
196	The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. Inflammatory Bowel Diseases, 2017, 23, 379-391.	1.9	88
197	Regression of apoptosis-resistant colorectal tumors by induction of necroptosis in mice. Journal of Experimental Medicine, 2017, 214, 1655-1662.	8.5	60
198	Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2017, 23, 617-627.	1.9	39

#	Article	IF	CITATIONS
199	Th9 cells in immunity and immunopathological diseases. Seminars in Immunopathology, 2017, 39, 1-4.	6.1	30
200	Mend Your Fences. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 33-46.	4.5	407
201	Chemically induced mouse models of acute and chronic intestinal inflammation. Nature Protocols, 2017, 12, 1295-1309.	12.0	862
202	Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing inÂMice With Colitis and Is Increased in Mucosa of Patients WithÂInflammatory Bowel Disease. Gastroenterology, 2017, 153, 123-138.e8.	1.3	72
203	Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity. New England Journal of Medicine, 2017, 376, 1292-1294.	27.0	233
204	Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therapeutic Advances in Gastroenterology, 2017, 10, 773-790.	3.2	22
205	Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visceral Medicine, 2017, 33, 82-88.	1.3	48
206	Three-Dimensional Cross-Sectional Light-Sheet Microscopy Imaging of the Inflamed Mouse Gut. Gastroenterology, 2017, 153, 898-900.	1.3	27
207	Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 1348-1359.	1.9	28
208	Precision Medicine in Inflammatory Bowel Diseases. Clinical Pharmacology and Therapeutics, 2017, 102, 623-632.	4.7	13
209	Professor Joachim Mössner Retires as Editor-in-Chief. Visceral Medicine, 2017, 33, 7-7.	1.3	0
210	Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders. Immunological Reviews, 2017, 278, 263-276.	6.0	20
211	The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond. Visceral Medicine, 2017, 33, 153-162.	1.3	6
212	Th9 cells in inflammatory bowel diseases. Seminars in Immunopathology, 2017, 39, 89-95.	6.1	50
213	Advanced endoscopy imaging in inflammatory bowel diseases. Gastrointestinal Endoscopy, 2017, 85, 496-508.	1.0	23
214	Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions. Journal of Crohn's and Colitis, 2017, 11, 221-228.	1.3	40
215	Rectal Delivery of a DNAzyme That Specifically Blocks theÂTranscription Factor GATA3 and Reduces Colitis in Mice. Gastroenterology, 2017, 152, 176-192.e5.	1.3	66
216	Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Frontiers in Immunology, 2017, 8, 764.	4.8	42

#	Article	IF	CITATIONS
217	Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders. Frontiers in Immunology, 2017, 8, 1371.	4.8	20
218	A Severe Case of Tuberculosis Radiologically and Endoscopically Mimicking Colorectal Cancer with Peritoneal Carcinomatosis. Case Reports in Gastrointestinal Medicine, 2017, 2017, 1-4.	0.3	7
219	Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AlO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC). Anticancer Research, 2017, 37, 3771-3779.	1.1	2
220	The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis. Journal of Clinical Investigation, 2016, 126, 4346-4360.	8.2	130
221	Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World Journal of Gastroenterology, 2016, 22, 9300.	3.3	165
222	Advances in hepatitis C therapy: What is the current state - what come's next?. World Journal of Hepatology, 2016, 8, 139.	2.0	85
223	Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer. Vaccines, 2016, 4, 5.	4.4	64
224	Ménage-Ã-Trois: The Ratio of Bicarbonate to CO2 and the pH Regulate the Capacity of Neutrophils to Form NETs. Frontiers in Immunology, 2016, 7, 583.	4.8	112
225	Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis. PLoS ONE, 2016, 11, e0158967.	2.5	45
226	Externalized decondensed neutrophil chromatin occludes pancreatic ducts and drives pancreatitis. Nature Communications, 2016, 7, 10973.	12.8	207
227	Confocal laser endomicroscopy for functional barrier imaging in Crohn's disease. Endoscopy, 2016, 48, 319-320.	1.8	2
228	Programming of Intestinal Epithelial Differentiation by IL-33 Derived from Pericryptal Fibroblasts in Response to Systemic Infection. Cell Reports, 2016, 15, 1743-1756.	6.4	100
229	Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2016, 10, 1132-1143.	1.3	15
230	Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 1294-1302.	1.3	62
231	Neuroendocrine tumor of the pancreas with cystic appearance mimicking a progressive intraductal papillary mucinous neoplasm: pitfall in medical imaging. Endoscopy, 2016, 48, E302-E303.	1.8	4
232	Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-β. Cell Cycle, 2016, 15, 2875-2881.	2.6	22
233	Chromoendoscopy in IBD: indispensable in real-life screening. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 688-690.	17.8	1
234	Acoustic radiation force impulse shear wave elastography (ARFI) of acute and chronic pancreatitis and pancreatic tumor. European Journal of Radiology, 2016, 85, 2211-2216.	2.6	56

#	Article	IF	CITATIONS
235	Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. Scientific Reports, 2016, 6, 30847.	3.3	48
236	Oxazolone-Induced Colitis as a Model of Th2 Immune Responses in the Intestinal Mucosa. Methods in Molecular Biology, 2016, 1422, 253-261.	0.9	19
237	Multispectral Optoacoustic Tomography in Crohn's Disease: Noninvasive Imaging of Disease Activity. Gastroenterology, 2016, 151, 238-240.	1.3	61
238	How will new and future therapies change our treatment of IBD?. Expert Review of Clinical Immunology, 2016, 12, 233-236.	3.0	3
239	IL-9 signaling as key driver of chronic inflammation in mucosal immunity. Cytokine and Growth Factor Reviews, 2016, 29, 93-99.	7.2	31
240	Loss of Survivin in Intestinal Epithelial Progenitor Cells Leads to Mitotic Catastrophe and Breakdown of Gut Immune Homeostasis. Cell Reports, 2016, 14, 1062-1073.	6.4	17
241	High-resolution Quantitative Computed Tomography Demonstrates Structural Defects in Cortical and Trabecular Bone in IBD Patients. Journal of Crohn's and Colitis, 2016, 10, 532-540.	1.3	28
242	Immune deficiency vs. immune excess in inflammatory bowel diseases— <i>STAT3</i> as a rheo-STAT of intestinal homeostasis. Journal of Leukocyte Biology, 2016, 99, 57-66.	3.3	9
243	Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut, 2016, 65, 1642-1664.	12.1	138
244	Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer. Gut, 2016, 65, 1139-1150.	12.1	59
245	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. Journal of Clinical Investigation, 2016, 126, 611-626.	8.2	38
246	Low Pretreatment Acoustic Radiation Force Impulse Imaging (ARFI) Values Predict Sustained Virological Response in Antiviral Hepatitis C Virus (HCV) Therapy. Medical Science Monitor, 2016, 22, 3500-3505.	1.1	1
247	Kruppel-like Factor 14 as Driver of Regulatory T-Cell Activity in Intestinal Inflammation. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 125-126.	4.5	0
248	Activation of Intestinal Epithelial Stat3 Orchestrates Tissue Defense during Gastrointestinal Infection. PLoS ONE, 2015, 10, e0118401.	2.5	48
249	Advances in imaging to allow personalized medicine in Crohn's disease. Current Opinion in Pharmacology, 2015, 23, 6-10.	3.5	1
250	Mechanisms of Immune Signaling in Colitis-Associated Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 6-16.	4.5	82
251	From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Archives of Toxicology, 2015, 89, 541-554.	4.2	37
252	Interleukin-12: Functional activities and implications for disease. Cytokine and Growth Factor Reviews, 2015, 26, 559-568.	7.2	178

#	Article	IF	CITATIONS
253	IL-9 regulates intestinal barrier function in experimental T cell-mediated colitis. Tissue Barriers, 2015, 3, e983777.	3.2	68
254	Confocal laser endomicroscopy for the differential diagnosis of ulcerative colitis and Crohn's disease: a pilot study. Endoscopy, 2015, 47, 437-443.	1.8	44
255	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. New England Journal of Medicine, 2015, 372, 1104-1113.	27.0	366
256	Functional Brain Imaging Reveals Rapid Blockade of Abdominal Pain Response Upon Anti-TNF Therapy in Crohn's Disease. Gastroenterology, 2015, 149, 864-866.	1.3	21
257	Endoscopic Therapy in Inflammatory Bowel Diseases. Visceral Medicine, 2015, 31, 280-286.	1.3	1
258	Usefulness of recombinant γ-gliadin 1 for identifying patients with celiac disease and monitoring adherence to a gluten-free diet. Journal of Allergy and Clinical Immunology, 2015, 136, 1607-1618.e3.	2.9	11
259	Molecular pathways controlling barrier function in IBD. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 67-68.	17.8	81
260	Caspase-8 controls the gut response to microbial challenges by Tnf-α-dependent and independent pathways. Gut, 2015, 64, 601-610.	12.1	84
261	Cyclosporine A Regulates Pro-Inflammatory Cytokine Production in Ulcerative Colitis. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 53-63.	2.3	12
262	First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy. World Journal of Gastroenterology, 2015, 21, 12963.	3.3	26
263	Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clinical and Experimental Rheumatology, 2015, 33, S19-28.	0.8	36
264	A true vascular aneurysm of the hepatic artery proper as a rare cause of nonmalignant painless jaundice. Endoscopy, 2014, 46, E652-E653.	1.8	1
265	Extensive small-bowel Crohn's disease detected by the newly introduced 360° panoramic viewing capsule endoscopy system. Endoscopy, 2014, 46, E353-E354.	1.8	9
266	Dual-focus narrow band imaging for the detection of intestinal metaplasia and atrophic gastritis. Endoscopy, 2014, 46, E47-E48.	1.8	4
267	Over-the-scope-clipping in colonic perforation caused small-bowel fixation and pneumoperitoneum requiring surgical repair. Endoscopy, 2014, 46, E314-E315.	1.8	2
268	Pleiotropic functions of TNF-α in the regulation of the intestinal epithelial response to inflammation. International Immunology, 2014, 26, 509-515.	4.0	144
269	Confocal Endomicroscopy Identifies Loss of Local Barrier Function in the Duodenum of Patients with Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 892-900.	1.9	71
270	The activating protein 1 transcription factor basic leucine zipper transcription factor, ATF-like (BATF), regulates lymphocyte- and mast cell–driven immune responses in the setting of allergic asthma. Journal of Allergy and Clinical Immunology, 2014, 133, 198-206.e9.	2.9	47

#	Article	IF	CITATIONS
271	Cytokines in inflammatory bowel disease. Nature Reviews Immunology, 2014, 14, 329-342.	22.7	1,941
272	IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature, 2014, 507, 366-370.	27.8	882
273	In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nature Medicine, 2014, 20, 313-318.	30.7	349
274	Colitis-associated neoplasia: molecular basis and clinical translation. Cellular and Molecular Life Sciences, 2014, 71, 3523-3535.	5.4	49
275	Regulation and pathophysiological role of epithelial turnover in the gut. Seminars in Cell and Developmental Biology, 2014, 35, 40-50.	5.0	34
276	Advanced endoscopic imaging techniques in Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 261-269.	1.3	30
277	Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Seminars in Immunology, 2014, 26, 75-79.	5.6	146
278	TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nature Immunology, 2014, 15, 676-686.	14.5	338
279	Long term follow up of through-the-scope balloon dilation as compared to strictureplasty and bowel resection of intestinal strictures in crohn's disease. International Journal of Clinical and Experimental Pathology, 2014, 7, 7419-31.	0.5	14
280	The esophageal mucosa and submucosa: immunohistology in GERD and Barrett's esophagus. Annals of the New York Academy of Sciences, 2013, 1300, 144-165.	3.8	5
281	Complex Roles of Caspases in the Pathogenesis of Inflammatory Bowel Disease. Gastroenterology, 2013, 144, 283-293.	1.3	85
282	Extensive small-bowel diverticulosis identified with the newly introduced On Demand Enteroscopy system. Endoscopy, 2013, 45, E350-E351.	1.8	5
283	Tissue resistance in the normal and diseased esophagus. Annals of the New York Academy of Sciences, 2013, 1300, 200-212.	3.8	5
284	How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy. Nature Medicine, 2013, 19, 822-824.	30.7	341
285	Tumor fibroblast–derived epiregulin promotes growth of colitis-associated neoplasms through ERK. Journal of Clinical Investigation, 2013, 123, 1428-1443.	8.2	95
286	Efficacy and toxicity of second-line AIO plus irinotecan (IRI) after pretreatment with AIO plus oxaliplatin (L-OHP) in the sequential therapy of metastatic colorectal cancer (CRC) Journal of Clinical Oncology, 2013, 31, 3561-3561.	1.6	0
287	Highlights in inflammatory bowel disease – from bench to bedside. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1229-1235.	2.3	13
288	Mucosal healing in inflammatory bowel diseases: a systematic review. Gut, 2012, 61, 1619-1635.	12.1	673

#	Article	IF	CITATIONS
289	The emerging role of T cell cytokines in non-small cell lung cancer. Cytokine and Growth Factor Reviews, 2012, 23, 315-322.	7.2	33
290	Targeting the VEGF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 5-13.	3.4	57
291	Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature, 2011, 477, 335-339.	27.8	737
292	Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages. Gastroenterology, 2011, 141, 2026-2038.	1.3	206
293	IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine and Growth Factor Reviews, 2011, 22, 83-89.	7.2	450
294	Confocal laser endomicroscopy and narrow-band imaging-aided endoscopy for in vivo imaging of colitis and colon cancer in mice. Nature Protocols, 2011, 6, 1471-1481.	12.0	53
295	New pathophysiological insights and modern treatment of IBD. Journal of Gastroenterology, 2010, 45, 571-583.	5.1	170
296	Assessment of Tumor Development and Wound Healing Using Endoscopic Techniques in Mice. Gastroenterology, 2010, 139, 1837-1843.e1.	1.3	33
297	Molecular Imaging: Interaction Between Basic and Clinical Science. Gastroenterology Clinics of North America, 2010, 39, 911-922.	2.2	9
298	STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. Journal of Experimental Medicine, 2009, 206, 1465-1472.	8.5	880
299	Colitis-associated cancer: the role of T cells in tumor development. Seminars in Immunopathology, 2009, 31, 249-256.	6.1	92
300	Translating Inflammatory Bowel Disease Research into Clinical Medicine. Immunity, 2009, 31, 357-361.	14.3	28
301	Novel cytokine-targeted therapies and intestinal inflammation. Current Opinion in Pharmacology, 2009, 9, 702-707.	3.5	24
302	RORÎ <sup>3</sup> -Expressing Th17 Cells Induce Murine Chronic Intestinal Inflammation via Redundant Effects of IL-17A and IL-17F. Gastroenterology, 2009, 136, 257-267.	1.3	408
303	Understanding the delayed onset of action of azathioprine in IBD: are we there yet?. Gut, 2009, 58, 325-326.	12.1	10
304	Identification of Epithelial Gaps in Human Small and Large Intestine by Confocal Endomicroscopy. Gastroenterology, 2007, 133, 1769-1778.	1.3	204
305	An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nature Protocols, 2007, 2, 1998-2004.	12.0	586
306	Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nature Protocols, 2007, 2, 2307-2311.	12.0	398

#	Article	IF	CITATIONS
307	TGF-Î <sup>2</sup> Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling. Immunity, 2004, 21, 491-501.	14.3	700
308	Treatment of T Cell-Dependent Experimental Colitis in SCID Mice by Local Administration of an Adenovirus Expressing IL-18 Antisense mRNA. Journal of Immunology, 2002, 168, 411-420.	0.8	123
309	Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet. Science, 2002, 295, 336-338.	12.6	562
310	Anti–interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology, 1999, 117, 1078-1088.	1.3	263